Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
VivoSim Labs, Inc. - Common Stock
(NQ:
VIVS
)
0.2752
-0.0059 (-2.10%)
Streaming Delayed Price
Updated: 11:15 AM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about VivoSim Labs, Inc. - Common Stock
< Previous
1
2
Next >
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
September 14, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
September 10, 2026
Via
AB Newswire
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
September 02, 2026
Via
AB Newswire
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
September 01, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Supply Chain
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 01, 2026
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans
From
VivoSim Labs, Inc.
Via
GlobeNewswire
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
September 01, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
August 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
August 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
August 25, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
August 17, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
August 14, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside
August 12, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Provides Financial and Listing Compliance Update
August 06, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
In today's session, these stocks are experiencing unusual volume.
↗
July 21, 2026
Via
Chartmill
MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
July 21, 2026
Via
Investor Brand Network
Topics
Animal Testing
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026
Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market
From
VivoSim Labs, Inc.
Via
GlobeNewswire
In today's session, these stocks are experiencing unusual volume.
↗
July 16, 2026
Via
Chartmill
Thursday's session: top gainers and losers
↗
July 16, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
July 16, 2026
Via
Chartmill
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
July 15, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 28, 2026
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
↗
April 01, 2026
Via
Chartmill
VivoSim Announces Pricing of up to a $4 Million Public Offering
April 01, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
March 24, 2026
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
March 03, 2026
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
February 11, 2026
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Why Is VIVS Stock Up 79% Today?
↗
January 30, 2026
VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.
Via
Stocktwits
Topics
Animal Testing
Let's take a look at the stocks that are in motion in today's session.
↗
January 30, 2026
Via
Chartmill
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
